Gilead Sciences Inc GILD

Morningstar Rating
$168.35 +1.82 (1.09%)
View Full Chart

Company Report

Price vs Fair Value

GILD is trading at a LOCK|%#d?<%L premium.
Price
$166.53
Fair Value
LOCK|Q>
Uncertainty
LOCK|g<d!
1-Star Price
LOCK|X.$
5-Star Price
LOCK|!.>
Economic Moat
LOCK|<!<
Capital Allocation
LOCK|MtQLG?@

Bulls Say, Bears Say

Bulls

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

Bears

Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.

News

Articles & Videos

Trading Information

Previous Close Price
$166.53
Day Range
$168.12–170.21
52-Week Range
$116.88–176.58
Bid/Ask
$168.26 / $168.42
Shares Outstanding
1.24B
Market Cap
$209.08B
Volume/Avg
2M / 6M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
6.69
Dividend Yield (Trailing)
1.95%
Dividend Yield (Forward)
1.97%
Dividend Payment Schedule
Mar, Jun, Sep, Dec
Total Yield
2.47%

Company Profile

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
17,000

Competitors

Valuation

Metric
GILD
ABBV
MRK
Price/Earnings (Normalized)
—32.1442.57
Price/Book Value
15.85—7.30
Price/Sales
6.697.624.88
Price/Cash Flow
14.0621.3914.84
Price/Earnings
GILD
ABBV
MRK

Financial Strength

Metric
GILD
ABBV
MRK
Quick Ratio
0.950.560.78
Current Ratio
1.380.871.35
Interest Coverage
−1.785.203.33
Quick Ratio
GILD
ABBV
MRK

Profitability

Metric
GILD
ABBV
MRK
Return on Assets (Normalized)
−0.60%16.61%5.90%
Return on Equity (Normalized)
−1.77%—16.36%
Return on Invested Capital (Normalized)
0.51%36.97%9.36%
Return on Assets
GILD
ABBV
MRK

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|?@&HD#t<LOCK|qp$1T
Johnson & Johnson
JNJ
LOCK|@cqJK&LOCK|@J$643B
AbbVie Inc
ABBV
LOCK|wD@#dJ#LOCK|g$^$501B
Roche Holding AG ADR
RHHBY
LOCK|^@&&$JPLOCK|CG$378B
Merck & Co Inc
MRK
LOCK|jc#QgQhLOCK|t>%$327B
Novartis AG ADR
NVS
LOCK|Sq>mj&wLOCK|$k>$285B
AstraZeneca PLC
AZN
LOCK|^#w#ltcLOCK|$wQ$271B
Amgen Inc
AMGN
LOCK|$x@MF@&LOCK|@x$237B
Novo Nordisk AS ADR
NVO
LOCK|<pW^?XLOCK|L<$172B

Sponsor Center